[HTML][HTML] BRAF gene and melanoma: Back to the future
As widely acknowledged, 40–50% of all melanoma patients harbour an activating BRAF
mutation (mostly BRAF V600E). The identification of the RAS–RAF–MEK–ERK (MAP kinase) …
mutation (mostly BRAF V600E). The identification of the RAS–RAF–MEK–ERK (MAP kinase) …
[HTML][HTML] Immune checkpoint inhibitors in hepatocellular carcinoma: current status and novel perspectives
P Federico, A Petrillo, P Giordano, D Bosso… - Cancers, 2020 - mdpi.com
Simple Summary Immune checkpoint inhibitors represent a promising treatment choice in
many kind of tumours, including hepatocellular carcinoma (HCC). In this review, we provide …
many kind of tumours, including hepatocellular carcinoma (HCC). In this review, we provide …
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma
M Ottaviano, S De Placido, PA Ascierto - Virchows Archiv, 2019 - Springer
Several researches have been carried over the last few decades to understand of how
cancer evades the immune system and thus to identify therapies that could directly act on …
cancer evades the immune system and thus to identify therapies that could directly act on …
[PDF][PDF] Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy
PA Zucali, T De Pas, G Palmieri… - Journal of Clinical …, 2018 - researchgate.net
Purpose No effective salvage treatments are available for patients with advanced/recurrent
thymoma (T) or thymic carcinoma (TC) who have progressed after platinum-based …
thymoma (T) or thymic carcinoma (TC) who have progressed after platinum-based …
[HTML][HTML] Distribution of mediastinal lesions across multi-institutional, international, radiology databases
Introduction Mediastinal lesions are uncommon; studies on their distribution are, in general,
small and from a single institution. Furthermore, these studies are usually based on …
small and from a single institution. Furthermore, these studies are usually based on …
[HTML][HTML] Epigenetic regulation in melanoma: facts and hopes
EF Giunta, G Arrichiello, M Curvietto, A Pappalardo… - Cells, 2021 - mdpi.com
Cutaneous melanoma is a lethal disease, even when diagnosed in advanced stages.
Although recent progress in biology and treatment has dramatically improved survival rates …
Although recent progress in biology and treatment has dramatically improved survival rates …
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)
M Imbimbo, M Ottaviano, M Vitali, A Fabbri… - Cancer Treatment …, 2018 - Elsevier
Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex
histopatological classification. Furthermore, the recent introduction of the first TNM staging …
histopatological classification. Furthermore, the recent introduction of the first TNM staging …
[HTML][HTML] Anorectal and genital mucosal melanoma: diagnostic challenges, current knowledge and therapeutic opportunities of rare melanomas
Mucosal melanomas (MM) are rare tumors, being less than 2% of all diagnosed melanomas,
comprising a variegated group of malignancies arising from melanocytes in virtually all …
comprising a variegated group of malignancies arising from melanocytes in virtually all …
[HTML][HTML] CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
D Mallardo, M Fordellone, A White, M Ottaviano… - Journal of Translational …, 2023 - Springer
Background Identifying response markers is highly needed to guide the treatment strategy in
patients with metastatic melanoma. Methods A retrospective study was carried out in …
patients with metastatic melanoma. Methods A retrospective study was carried out in …
[HTML][HTML] Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response
G Cernera, M Gelzo, P De Placido… - Frontiers in …, 2023 - frontiersin.org
Background Thymic epithelial tumors (TETs) are rare malignancies with heterogeneous
clinical manifestations. The high frequency of autoimmune paraneoplastic disorders …
clinical manifestations. The high frequency of autoimmune paraneoplastic disorders …